Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol. 1996

C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
Istituto di Terapia Medica Sistematica, Università La Sapienza, Roma, Italia.

Plasma levels of fibrinogen, factor VIIc and prothrombin fragment F1 + 2, a marker of thrombin generation in vivo, were studied in 68 subjects with serum total cholesterol (TC) levels between 135 and 349 mg/dl but without clinical evidence of cardiovascular disease and other atherosclerotic risk factors. F1 + 2 plasma levels were directly correlated with TC (p < 0.0004), low-density lipoprotein cholesterol (LDL-C; p < 0.0018) and factor VIIc (p < 0.024). Thirty-five subjects with TC greater than 249 mg/dl (median value of the whole group) showed higher levels of F1 + 2 (p < 0.0001) and fibrinogen (p < 0.0015) than those with TC lower than 249 mg/dl. In subjects with TC > 249 mg/dl and F1 + 2 > 1.2 nM (median value of the whole group), a cholesterol-lowering drug (simvastatin) was able to reduce F1 + 2 (p < 0.009) as well as TC and LDL-C. This study shows a relationship between serum cholesterol and the rate of thrombin generation supporting the hypothesis that a hypercoagulable state may occur in hypercholesterolemic subjects before the onset of clinical evidence of atherosclerotic cardiovascular disease.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008148 Lovastatin A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. Lovastatin, 1 alpha-Isomer,Mevinolin,6-Methylcompactin,Lovastatin, (1 alpha(S*))-Isomer,MK-803,Mevacor,Monacolin K,1 alpha-Isomer Lovastatin,6 Methylcompactin,Lovastatin, 1 alpha Isomer,MK 803,MK803,alpha-Isomer Lovastatin, 1
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002791 Cholesterol, Dietary Cholesterol present in food, especially in animal products. Dietary Cholesterol
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
October 1993, Deutsche medizinische Wochenschrift (1946),
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
December 2004, Nihon rinsho. Japanese journal of clinical medicine,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
June 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
July 1994, Thrombosis research,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
August 1992, Sangre,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
October 2021, International journal of laboratory hematology,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
January 1993, International journal of cardiology,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
May 1997, Thrombosis and haemostasis,
C Alessandri, and S Basili, and M Maurelli, and D Bracaglia, and P Andreozzi, and M Pergolini, and C Cordova
December 2017, Journal of orthopaedics,
Copied contents to your clipboard!